No claims for monetary damages in US patent case: Dr Reddy’s Labs

V Rishi Kumar Hyderabad | Updated on January 13, 2018 Published on February 17, 2017


Dr Reddy's Laboratories has said there are no claims for monetary damages against the company in the unfavourable ruling in a US court with regard to anti-nausea injection.

In a statement filed with the BSE, Dr Reddy's said, “In this regard, we would like to state that there are no claims against the company for monetary damages because the proposed palonosetron product has not been marketed.”

As for quantum claims, it maintained the claims only sought injuctive relief against the company to prohibit the manufacturing, use, import and sale of the company's palonosetron product prior to expiration of the patents-in-suit. Therefore, Dr Reddy's stated it believes there is no monetary compensation or penalty damages owed to Helsinn due to this decision. The company issued this statement following a clarification sought about the company press statement issued on February 16, about Dr Reddy's announcement made on US district court's opinion relating to patent infringement.

The Hyderabad-based pharma major had informed the BSE it received an unfavourable ruling in a US court on a patent infringement matter over Aloxi.

The company had informed that a District Court in New Jersey, United States, issued its opinion regarding palonosetron product, pursuant to a paper NDA of the Food, Drug and Cosmetic Act.

It further stated that the Court found that Dr Reddy's proposed palonosetron hydrochloride 0.25 mg/5 ml product infringes certain claims of the US patents and that the certain asserted claims were not invalid.

Published on February 17, 2017
This article is closed for comments.
Please Email the Editor